Last reviewed · How we verify
Cyclical neutropenia — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Neupogen | Filgrastim-Aafi | Amgen | Colony-stimulating factor (CSF); leukocyte growth factor | G-CSF receptor (granulocyte colony-stimulating factor receptor) | 1991-01-01 | |
| Neupogen | Neupogen | University of Chicago | Granulocyte colony-stimulating factor receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Amgen · 1 drug in Cyclical neutropenia
- University of Chicago · 1 drug in Cyclical neutropenia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Cyclical neutropenia:
- Cyclical neutropenia treatment updates — RSS
- Cyclical neutropenia treatment updates — Atom
- Cyclical neutropenia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Cyclical neutropenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cyclical-neutropenia. Accessed 2026-06-10.
Related
- Cyclical neutropenia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing